Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICROGESTIN FE 1/20 vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone acetate (progestin). Suppresses gonadotropins via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial lining.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years who have achieved menarche)
Prevention of pregnancy
One tablet orally once daily, containing norethindrone acetate 1 mg and ethinyl estradiol 20 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets) or continuous cycling per prescribing information.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Norethindrone: 5-14 hours (mean 8 hours); Ethinyl estradiol: 12-24 hours (mean 18 hours); Steady-state in 5-7 days
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Primarily hepatic via CYP3A4. Norethindrone acetate undergoes reduction and conjugation; ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal: ~50-60% as metabolites; Fecal: ~30-40% as metabolites; Biliary: minor; <1% unchanged
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Norethindrone: 61% to albumin, 36% to SHBG; Ethinyl estradiol: 98% to albumin
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Norethindrone: 2.1 L/kg; Ethinyl estradiol: 2.8 L/kg
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: Norethindrone ~65%; Ethinyl estradiol ~40-45%
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dosage adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min) or end-stage renal disease; use caution due to potential for estrogen accumulation and metabolic effects.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). For Child-Pugh Class A or B, use only if benefits outweigh risks; monitor for adverse effects; consider alternative contraception due to altered hormone metabolism.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Post-menarchal pediatric patients: Same dosing as adults. Safety and efficacy established in adolescents; use according to standard adult regimen.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for postmenopausal women; no specific dosing recommendations. Use caution in elderly if prescribed off-label due to increased risk of thromboembolic events, cardiovascular disease, and malignancy.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially >35 years) and with heavy smoking (≥15 cigarettes/day). Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Increased risk of thromboembolic disorders (e.g., stroke, MI, VTE), especially in smokers and women with hypertension, diabetes, or hyperlipidemias,Elevated risk of cervical and breast cancer,Hepatic neoplasia (benign and malignant),Gallbladder disease,Carbohydrate and lipid metabolism alterations,Hypertension,Headache/migraine,Irregular bleeding,Depression,Contact lens intolerance,Possible decreased efficacy with hepatic enzyme inducers,Discontinue if jaundice, visual disturbances, or thromboembolic symptoms occur
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Heavy smoking (≥15 cigarettes/day) and age >35 years,Uncontrolled hypertension,Diabetes with vascular involvement,Migraine with focal neurological symptoms (current or history)
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No specific food restrictions. Grapefruit juice may modestly increase estrogen levels but is not contraindicated. High-fat meals may increase estrogen absorption. Calcium-rich foods or supplements may reduce iron absorption from placebo tablets; separate intake by several hours.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
FDA Pregnancy Category X. Estrogens and progestins are contraindicated in pregnancy due to risk of fetal harm. Epidemiological studies have not revealed an increased risk of birth defects in women who inadvertently used combined oral contraceptives during early pregnancy. However, use of progestins alone during the first trimester of pregnancy is associated with genital abnormalities in female fetuses, including hypospadias and mild clitoral hypertrophy. Post-fertilization effects: no evidence of increased risk of spontaneous abortion or low birth weight with inadvertent use during early pregnancy. Second and third trimesters: no therapeutic indication; potential for estrogenic effects on fetal development, but data are limited due to contraindication.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Small amounts of contraceptive steroids and their metabolites are excreted in human milk, with an estimated infant dose of 0.1% to 1% of maternal dose per kg/day. The M/P ratio for norethindrone is approximately 0.6. Breastfeeding safety: use is not recommended while breastfeeding, especially with early postpartum use, due to potential reduction in milk production and content, as well as unknown long-term effects on infant development. Alternative contraception methods should be considered.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
No dosing adjustments recommended because the drug is contraindicated in pregnancy. If inadvertently used, the drug should be discontinued immediately. No clinical studies have established safe or effective dosing regimens during pregnancy.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg with ferrous fumarate 75 mg as placebo tablets. Iron supplementation may improve hematologic parameters in anemic patients. Bleeding irregularities are common in first 3-6 months; counsel on adherence to prevent breakthrough bleeding. Caution in patients with migraine with aura, history of VTE, or smokers over 35. CYP3A4 inducers like rifampin may reduce efficacy; consider alternative contraception.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one tablet daily at the same time each day, preferably with food to reduce nausea.,The last 7 tablets (brown) contain iron and are inactive; continue taking them to maintain the habit.,Bleeding may be irregular initially; report heavy or prolonged bleeding to your healthcare provider.,Do not smoke while taking this medication, especially if over 35, as it increases clot risk.,Use additional non-hormonal contraception (e.g., condoms) if you miss a pill or have vomiting/diarrhea.,Store at room temperature away from moisture and heat.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICROGESTIN FE 1/20 vs ALYACEN 1/35, answered by our medical review team.
MICROGESTIN FE 1/20 is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone acetate (progestin). Suppresses gonadotropins via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial lining.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICROGESTIN FE 1/20 and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICROGESTIN FE 1/20 is: One tablet orally once daily, containing norethindrone acetate 1 mg and ethinyl estradiol 20 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets) or continuous cycling per prescribing information.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICROGESTIN FE 1/20 and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICROGESTIN FE 1/20 is classified as Category C. FDA Pregnancy Category X. Estrogens and progestins are contraindicated in pregnancy due to risk of fetal harm. Epidemiological studies have not revealed an increased risk of birth . ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.